Amgen Inc.

What does Amgen own?
Amgen owns the Amgen brand and product brands including Enbrel, Prolia, Otezla, Neulasta, Repatha, Tezspire, and others. The Horizon acquisition added Tepezza, Krystexxa, and Uplizna.

Is Amgen publicly traded?
Yes. Amgen trades on Nasdaq under ticker AMGN and is a component of the S&P 500 and Dow Jones Industrial Average.

Who founded Amgen?
George Rathmann founded Applied Molecular Genetics in 1980 in Thousand Oaks, California. The name Amgen derives from the original.

Where is Amgen headquartered?
Amgen is headquartered in Thousand Oaks, California, USA.

Who owns Amgen?
Amgen is owned by public shareholders with no controlling investor. Robert Bradway serves as Chairman and CEO.

What is Amgen's revenue?
Amgen reported FY2025 total revenues of $36.8 billion, up 10%, with GAAP net income of $7.7 billion and non-GAAP EPS of $21.84.

What does Amgen make?
Amgen makes biologic medicines including Enbrel for rheumatoid arthritis, Prolia for osteoporosis, Otezla for psoriasis, and oncology and rare disease treatments.

George Rathmann founded Applied Molecular Genetics in 1980 in Thousand Oaks, California, one of the pioneering biotechnology companies applying recombinant DNA technology to medicine. The name Amgen derives from the original.

The company's first blockbuster, Epogen (epoetin alfa) for anemia, launched in 1989 and made Amgen profitable, followed by Neupogen (filgrastim) in 1991 for chemotherapy side effects. These two products established the biologics manufacturing and commercial model that defined the industry.

The 2002 acquisition of Immunex for $16 billion added Enbrel, the rheumatoid arthritis biologic that became Amgen's largest product and one of the highest-selling drugs in pharmaceutical history. Subsequent acquisitions built the oncology and inflammation portfolio.

The 2023 acquisition of Horizon Therapeutics for approximately $27.8 billion added rare disease drugs including Tepezza, Krystexxa, and Uplizna, the largest deal in Amgen's history, expanding the portfolio into orphan diseases while the core blockbuster business continued generating cash for pipeline investment.

Amgen's sustainability program covers operational emissions, water and waste at biologics manufacturing sites, and access-to-medicine initiatives including the Amgen Foundation's science education programs that are among the largest corporate STEM education investments.

As a pharmaceutical manufacturer, the company operates under FDA and global regulatory frameworks for drug safety, manufacturing quality, and marketing practices, with compliance managed through standard industry processes.

• Fortune 500: Amgen ranks on the Fortune 500 by revenue.
• Dow Jones Industrial Average: Amgen is a component of the Dow, among the few biotechs at that level.
• Innovation recognition: The company's drug development record including first-in-class biologics has received industry recognition.

IRA drug pricing impact: Otezla's selection for Medicare price negotiation produced the $1.2 billion impairment in FY2025, part of the industry-wide IRA drug pricing debate affecting pharmaceutical economics.

Drug pricing broadly: Amgen faces the same US drug pricing scrutiny as all major pharma, including Enbrel's high US list price relative to international markets and biosimilar competition questions.

Patent and exclusivity litigation: The company engages in routine but significant patent litigation defending its biologics against biosimilar challenges, and similarly challenges others' patents for its own biosimilars.